Literature DB >> 23090522

Continuation of the etonogestrel implant in women undergoing immediate postabortion placement.

Tessa Madden1, David L Eisenberg, Qiuhong Zhao, Christina Buckel, Gina M Secura, Jeffrey F Peipert.   

Abstract

OBJECTIVE: To estimate whether women who receive an immediate postabortion etonogestrel subdermal implant have higher discontinuation rates than women who undergo an interval insertion (insertion not associated with a recent pregnancy).
METHODS: This was a secondary analysis of the Contraceptive CHOICE Project. We compared 12-month continuation rates for the subdermal implant between women undergoing immediate postabortion placement and women who underwent an interval placement. Continuation rates were compared using Kaplan-Meier estimator of survival function and Cox proportional hazard models.
RESULTS: Over the study period, 141 women received the implant immediately postabortion and 935 women underwent an interval placement. The 12-month continuation rates were similar: 81.5% among women undergoing immediate postabortion placement and 82.8% among women undergoing interval placement (P=.54). In the survival analysis, women who received an immediate postabortion implant were no more likely to discontinue their method than women who had an interval placement (adjusted hazard ratio 1.04, 95% confidence interval 0.68-1.60). The most common reason given for discontinuation was frequent or irregular bleeding, which was reported by 65.4% of women discontinuing in the immediate postabortion group and 56.7% in the interval group.
CONCLUSION: Women who undergo immediate postabortion placement of the subdermal implant have high rates of continuation that are equivalent to women undergoing interval insertion. Immediate postabortion long-acting reversible contraceptives should be available to women undergoing induced abortion to decrease the risk of repeat unplanned pregnancy. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23090522      PMCID: PMC3711380          DOI: 10.1097/aog.0b013e3182632cd6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  15 in total

1.  A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group.

Authors:  H B Croxatto; J Urbancsek; R Massai; H Coelingh Bennink; A van Beek
Journal:  Hum Reprod       Date:  1999-04       Impact factor: 6.918

2.  Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth.

Authors:  J Trussell; B Vaughan
Journal:  Fam Plann Perspect       Date:  1999 Mar-Apr

3.  Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.

Authors:  Mary Short; Dominique Dallay; Salmon Omokanye; Jens Ulrich Hanisch; Pirjo Inki
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-12-27       Impact factor: 1.848

4.  Abortion in the United States: incidence and access to services, 2005.

Authors:  Rachel K Jones; Mia R S Zolna; Stanley K Henshaw; Lawrence B Finer
Journal:  Perspect Sex Reprod Health       Date:  2008-03

5.  Factors associated with contraceptive use and nonuse, United States, 2004.

Authors:  Jennifer J Frost; Susheela Singh; Lawrence B Finer
Journal:  Perspect Sex Reprod Health       Date:  2007-06

6.  The potential of long-acting reversible contraception to decrease unintended pregnancy.

Authors:  J Joseph Speidel; Cynthia C Harper; Wayne C Shields
Journal:  Contraception       Date:  2008-07-09       Impact factor: 3.375

7.  Unintended pregnancy in the United States: incidence and disparities, 2006.

Authors:  Lawrence B Finer; Mia R Zolna
Journal:  Contraception       Date:  2011-08-24       Impact factor: 3.375

8.  Impact of long-acting reversible contraception on return for repeat abortion.

Authors:  Sally B Rose; Beverley A Lawton
Journal:  Am J Obstet Gynecol       Date:  2011-07-13       Impact factor: 8.661

9.  Perceived and insurance-related barriers to the provision of contraceptive services in U.S. abortion care settings.

Authors:  Megan L Kavanaugh; Rachel K Jones; Lawrence B Finer
Journal:  Womens Health Issues       Date:  2011 May-Jun

10.  Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion.

Authors:  Suzan Goodman; Sarah K Hendlish; Matthew F Reeves; Anne Foster-Rosales
Journal:  Contraception       Date:  2008-05-14       Impact factor: 3.375

View more
  6 in total

1.  Postabortion Contraceptive Use and Continuation When Long-Acting Reversible Contraception Is Free.

Authors:  Vinita Goyal; Caitlin Canfield; Abigail R A Aiken; Amna Dermish; Joseph E Potter
Journal:  Obstet Gynecol       Date:  2017-04       Impact factor: 7.661

Review 2.  Immediate versus delayed postabortal insertion of contraceptive implant.

Authors:  Jen Sothornwit; Nuntasiri Eamudomkarn; Pisake Lumbiganon; Nampet Jampathong; Mario R Festin; Lingling Salang
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

3.  The contraceptive CHOICE project round up: what we did and what we learned.

Authors:  Colleen McNicholas; Tessa Madden; Gina Secura; Jeffrey F Peipert
Journal:  Clin Obstet Gynecol       Date:  2014-12       Impact factor: 2.190

4.  Determinants of early discontinuation of etonogestrel sub-dermal implant among reproductive-age women in Legambo district, Northeast Ethiopia: An unmatched case-control study.

Authors:  Yesuf Yimer; Niguss Cherie; Yitaysh Damtie
Journal:  SAGE Open Med       Date:  2022-03-29

Review 5.  Safety and Benefits of Contraceptives Implants: A Systematic Review.

Authors:  Morena Luigia Rocca; Anna Rita Palumbo; Federica Visconti; Costantino Di Carlo
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-08

6.  Prevalence and factors associated with early discontinuation rate of Implanon utilization among women who ever used Implanon in Kucha District Gamo Gofa Zone, Southern Ethiopia.

Authors: 
Journal:  BMC Womens Health       Date:  2020-10-23       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.